Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone-Reference-Cited by-同舟云学术

Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone

Published:2023-12-25 Issue: Volume: Page:
ISSN:1359-4184
Container-title:Molecular Psychiatry
language:en
Short-container-title:Mol Psychiatry

Author:

Levinstein Marjorie R.^ORCID,De Oliveira Paulo A.,Casajuana-Martin Nil^ORCID,Quiroz Cesar,Budinich Reece C.,Rais Rana,Rea William,Ventriglia Emilya N.,Llopart Natàlia^ORCID,Casadó-Anguera Verònica,Moreno Estefanía^ORCID,Walther Donna,Glatfelter Grant C.,Weinshenker David^ORCID,Zarate Carlos A.,Casadó Vicent^ORCID,Baumann Michael H.,Pardo Leonardo,Ferré Sergi^ORCID,Michaelides Michael^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse

Ministry of Economy and Competitiveness | Agencia Estatal de Investigación

Generalitat de Catalunya

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Psychiatry and Mental health,Molecular Biology

Link

https://www.nature.com/articles/s41380-023-02353-z.pdf

Reference53 articles.

1. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA. 1965;193:646–50.

2. Salsitz E, Wiegand T. Pharmacotherapy of opioid addiction: “putting a real face on a false demon". J Med Toxicol. 2016;12:58–63.

3. Chem KK. Pharmacology of methadone and related compounds. Ann N Y Acad Sci. 1948;51:83–97.

4. Casati A, Piontek D, Pfeiffer-Gerschel T. Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment. Subst Abuse Treat Prev Policy. 2014;9:19.

5. Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, et al. REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry. 2022;179:122–31.